Indian Pharma Market Grows 7.5% in Feb 2025, But Respiratory Segment Declines by 4.6%
The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline in unit sales.
Delhi: The Indian pharmaceutical market (IPM) continued its upward momentum in February 2025, registering a 7.5% monthly growth in value, according to the latest PharmaTrac MAT report. The industry also recorded a 1.5% increase in unit sales compared to January 2025, reflecting steady demand across key therapeutic segments. On a year-on-year basis, the market saw an 8.1% growth compared to February 2024.
Therapy-wise Performance: Cardiac and Gastro Segments Drive Monthly Growth
The cardiac therapy segment saw the highest monthly increase, growing 9.2% in value and 1.5% in units compared to January 2025. The gastrointestinal segment followed closely, reporting an 8.6% value growth and 4.2% unit growth, indicating rising demand for digestive health medications.
The anti-infectives segment saw a 5.1% value growth month-on-month, despite a 2.1% dip in unit sales. Meanwhile, anti-diabetics posted 7.8% growth in value and 2.4% growth in unit sales.
The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline in unit sales. Pain and analgesics recorded 7.9% value growth, though units sold fell slightly by 0.6%.
Corporate Performance: Sun Pharma Maintains Lead in Monthly Sales
Among pharmaceutical companies, Sun Pharma (including Ranbaxy) continued its dominance, reporting a 10.2% monthly growth in value, reaching Rs 18,455 crore in sales for February 2025. Abbott (including Novo Nordisk and Abbott Healthcare) recorded Rs 13,246 crore in monthly sales, reflecting a 6.8% growth.
Cipla, a leader in respiratory and chronic therapies, reported Rs 11,639 crore in sales for February 2025, showing a 6.9% increase over the previous month. Mankind Pharma and Bharat Serums, known for their presence in women’s health and fertility, posted Rs 12,611 crore in monthly sales, growing by 8.2%.
Other notable performers included Dr. Reddy’s Laboratories, which grew by 9.4% month-on-month, and Zydus Lifesciences, which saw an 8.0% increase in value sales.
Top-Selling Brands: Augmentin, Glycomet GP, and Mixtard Register Monthly Growth
Among the best-performing brands in February 2025, GlaxoSmithKline’s Augmentin led with Rs 817 crore in sales, reflecting a 5.2% increase over January 2025. USV’s Glycomet GP, a leading anti-diabetic brand, followed with Rs 800 crore in sales, registering a 3.5% monthly growth.
Abbott’s Mixtard, a widely used insulin brand, recorded Rs 776 crore in sales, while Alkem’s Pan grew 7.9% month-on-month, reaching Rs 759 crore in sales.
Growth Drivers: Pricing and New Launches Boost Sales
Price growth remained the primary factor driving monthly market expansion, contributing 5.1% to overall growth. New product launches accounted for 2.1% growth, while changes in volume had a limited impact, registering a 0.3% increase.
The February 2025 market value was 7.5% higher than January 2025, showcasing consistent demand. This follows a 6.3% monthly growth recorded in January, highlighting a positive trend in pharma sales.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.